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Protein kinase CK2 is a multifunctional kinase of
medical importance that is dysregulated in many
cancers. In this study, polyoxometalates were identi-
fied as original CK2 inhibitors. [P2Mo18O62]
6 has the
most potent activity. It inhibits the kinase in the nano-
molar range by targeting key structural elements
located outside the ATP- and peptide substrate-
binding sites. Several polyoxometalate derivatives
exhibit strong inhibitory efficiency, with IC50 values
% 10 nM. Furthermore, these inorganic compounds
show a striking specificity for CK2 when tested in
a panel of 29 kinases. Therefore, polyoxometalates
are effective CK2 inhibitors in terms of both efficiency
and selectivity and represent nonclassical kinase
inhibitors that interact with CK2 in a unique way.
This binding mode may provide an exploitable mech-
anism for developing potent drugs with desirable
properties, such as enhanced selectivity relative to
ATP-mimetic inhibitors.
INTRODUCTION
Dysregulation of signal transduction pathways underlies many
diseases, including cancers. These pathways are rich in protein
kinases. Perturbation of these protein kinase-mediated regula-
tory networks can lead to various disease states that might be
amenable to therapeutic intervention. Thus, protein kinases are
major therapeutic targets, and several kinase inhibitors have
demonstrated powerful clinical activity in tumors in which the
target kinase is deregulated (Bogoyevitch and Fairlie, 2007).
Protein kinase CK2 (formerly known as Casein Kinase II) is
a multifunctional serine/threonine kinase that plays critical roles
in cell growth, cell differentiation, apoptosis, and oncogenic
transformation (Ahmed et al., 2002; Litchfield, 2003). CK2 is in-
volved in animal development and oncogenesis, where it has
been found to be dysregulated. Its dual function in promoting
cell growth and suppressing apoptosis confers a relevant onco-Chemistry & Biology 15genic potential (Tawfic et al., 2001). Association of aberrant CK2
expression with unfavorable prognostic markers in prostate
cancer (Laramas et al., 2007) and in acute myeloid leukemia
(Kim et al., 2007) confers to CK2 the status of relevant patho-
physiological target, thus supporting the identification and the
characterization of chemical inhibitors (Pagano et al., 2006).
Hence, numerous CK2 inhibitors appeared over the past few
years in the literature: halogenated compounds TBB (4,5,6,7-tet-
rabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,
6,7-tetrabromo-1H-benzimidazole) (Sarno et al., 2003; Pagano
et al., 2004), condensed polyphenolic derivatives (anthraqui-
nones, xanthenones, fluorenones, and coumarins) (Meggio
et al., 2004), and a 7-substituted indoloquinazoline compound
(Vangrevelinghe et al., 2003) have been reported to inhibit CK2
in the micromolar range. All of these inhibitors are aromatic or-
ganic compounds and behave as ATP mimetics, highlighting
the necessity to search among new classes of molecules for
new inhibitors. Indeed a recent report has identified a platinum
complex as a nanomolar inhibitor of glycogen synthase kinase
3 (GSK-3a) (Williams et al., 2007). However, the compound
also binds to the ATP-binding site. Screening of very diverse
libraries is a way to find new active compounds. Therefore,
we used this strategy to develop non-ATP-competitive CK2
inhibitors.
Using high-throughput screening of highly diverse chemical
libraries, we have identified inorganic CK2 inhibitors, namely,
polyoxometalates (POMs). These are aggregates of early-tran-
sition metal ions (mainly M = VV, MoVI, or WVI) and oxo ligands
(Pope, 2003), which are formed in solution by condensation re-
actions of the oxo anion MO4
n. Depending on the boundary
conditions (temperature, pH, and composition of the solution),
many different structures arise. These nanometer-sized com-
pounds bear multiple negative charges distributed over the
whole surface, thus keeping the charge density relatively low.
Figure 1 shows typical examples of POMs relevant to this
work.
Antiviral, antitumoral, and antibiotic activities have been re-
ported for several POMs (Yamase, 2005; Hasenknopf, 2005;
Rhule et al., 1998). Although the molecular target of the POM
is generally unknown, several papers report detailed study of
the interaction between POMs and a given protein (Herve´, 683–692, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 683
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1996; Judd et al., 2001). Binding of POMs to Escherichia coli
DNA polymerase (Herve´ et al., 1983), to HIV-1 reverse transcrip-
tase (Sarafianos et al., 1996), and to protease (Judd et al., 2001)
was established. In the former two cases, the polyanionic POM
binds to the DNA-binding site, whereas, in the latter case, it
binds outside the active site. Several classic POMs bind to Ba-
sic Fibroblast Growth Factor, a globular heparin-binding poly-
peptide, presumably at a cationic pocket. Then, the structure
of the protein is affected, which results in a stabilizing effect rel-
ative to the free protein (Wu et al., 2005; Sun et al., 2004). Dec-
avanadate has a high affinity for myosin and the sarcoplasmic
reticulum calcium pump, and, in some biological systems, the
effects of vanadium can be related to the presence of decava-
nadate (Aureliano and Gandara, 2005). Decavanadate was also
reported to be an antisubstrate inhibitor of cAMP-dependent
protein kinase (Pluskey et al., 1997). Polyoxotungstates were
identified as potent inhibitors of ectonucleoside triphosphate
diphosphohydrolase, and some displayed a useful selectivity
pattern (Mu¨ller et al., 2006). POMs are also known to selectively
precipitate some types of proteins, for instance the prion
protein (Lee et al., 2005).
RESULTS AND DISCUSSION
High-Throughput Identification of Polyoxometalates
The National Cancer Institute (NCI) Diversity Set (1985 com-
pounds) and the Mechanistic Diversity Set (879 compounds)
were screened at concentrations of 15 mM by using an in vitro ki-
nase assay. A secondary screen was performed at concentra-
tions of 1.5 mM by using a standard radioactive kinase assay
with high ATP concentrations (100 mM; Km for ATP of recombi-
nant CK2, 25 mM) to increase the probability of isolating non-
ATP-competitive compounds. POMs were identified among
Figure 1. Ball-and-Stick Representation of
Typical Polyoxometalates
(A) Dawson structure, a-[P2W18O62]
6.
(B) Preyssler structure, [NaP5W30O110]
14.
(C) Keggin structure, a-[PW12O40]
3.
(D) Heptamolybdate, [Mo7O24]
6.
(E) Lindqvist structure, [Mo6O19]
2.
W, Mo = large light-gray spheres, O = small dark-
gray spheres, other elements noted on the figure.
active hits. We therefore investigated
that class more closely by testing a
series of POMs (see Table S1 available
online).
The highest inhibition was observed
for K6[P2Mo18O62], a phosphomolybdate
with the Dawson structure (Figure 1A). De-
rivatives of the Dawson structure showed
moderate to high inhibition of CK2.
The Preyssler anion K14[NaP5W30O110]
(Figure 1B) also had good activity as an
inhibitor, as does the giant phosphotung-
state K28Li5H7[P8W48O184]. Smaller
POMs such as Keggin derivatives
[XM12O40]
n (Figure 1C), the heptamolybdate [Mo7O24]
6 (1D),
or the Lindqvist molybdate [Mo6O18]
2 (1E), were less active.
Structure-Activity Relationship of POMs
To better quantify the inhibitory effect of POMs, and to attempt to
correlate it to structural or compositional features, we deter-
mined the IC50 value of a series of POMs. We included in this se-
ries a number of Preyssler structures with different lanthanide
ions, Dawson structures with lanthanides or organotin substitu-
ents, and Keggin ions with organotin substituents in order to
compare the effects of structures (Preyssler, Dawson, Keggin)
and composition/functionalization (lanthanides, organotin
groups). We also included (NH4)18[NaSb9W21O86] (HPA-23) and
one of its lanthanide derivatives as additional examples of
a highly charged, very large POM. Our results are presented in
Table 1.
It can be concluded that the POM structure mainly determines
its inhibitory effect. Data indicate that the inhibitory efficiency in-
creases with the size and the charge of the administered POM.
Small Keggin ions are inactive, larger Dawson compounds are
moderately active, and the largest and most charged Preyssler
ions are the best subgroup of inhibitors. Derivatives within the
same POM family are of comparable activity. It is not surprising
to find more pronounced differences between the different Daw-
son compounds, where the modifications are located at the pe-
riphery of the framework, compared to the series of Preyssler
ions, where the different lanthanide ions are buried in the center
of the structure. There are no clear trends to explain the variation
of activity caused by the side chain modifications among the
organotin-substituted Dawson POMs. However, the organic
groups did not include any particular protein-recognition motif.
More designed organic-inorganic hybrids might have an enhan-
ced activity, provided we get a clear picture of the POM-CK2
interaction.
684 Chemistry & Biology 15, 683–692, July 21, 2008 ª2008 Elsevier Ltd All rights reserved
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Formula M (g$mol1) IC50 (nM) Type
K6[P2Mo18O62] 3015 1.4 Dawson
K12[LuP5W30O110] 8076 1 Preyssler
K12[SmP5W30O110] 8051 3 Preyssler
K12[YbP5W30O110] 8174 3 Preyssler
{N(C4H9)4}7 a1-[P2W17O61{Sn(CH2)2COOH}] 6084 3.5 Dawson (organic derivative, belt)
K12[YP5W30O110] 7990 5 Preyssler
[{N(C4H9)4}7 a2-[P2W17O61{Sn(CH2)2CHO}] 6068 7.5 Dawson (organic derivative, cap)
(NH4)18[NaSb9W21O86] 6681 8 Giant POM (HPA-23)
{N(C4H9)4}7 a2-[P2W17O61{Sn(CH2)2CONBn2}] 6060 11 Dawson (organic derivative, cap)
{N(C4H9)4}7 a2-[P2W17O61{Sn(CH2)2COOH}] 4849 13 Dawson (organic derivative, cap)
(NH4)16[EuSb9W21O86] 6810 13 Giant POM (HPA-23 lanthanide
derivative)
{N(C4H9)4}3 [PW12O40] 3604 60 Keggin
{N(C4H9)4}7 a1-[P2W17O61{Sn(CH2)2CONHBn2}] 6232 70 Dawson (organic derivative, belt)
K21H4[EuAs4W40O140] 10872 70 Giant POM
{N(C4H9)4}7 a1-[P2W17O61{Sn(CH2)2CONHCH2-m-C6H4CH2NHBoc}] 6271 >7 Dawson (organic derivative, belt)
K7[a1-YbP2W17O61] 4681 >7 Dawson (lanthanide derivative, belt)
{N(C4H9)4}7 a1-[P2W17O61{Sn(CH2)2CO-(L-Tyr)-O
tBu}] 6273 >7 Dawson (organic derivative, belt)
{N(C4H9)4}7 a1-[P2W17O61{Sn(CH2)2CO-(Gly)-O
tBu}] 6166 >7 Dawson (organic derivative, belt)
K7[a1-EuP2W17O61] 4660 >7 Dawson (lanthanide derivative, belt)
K7[a1-SmP2W17O61] 4659 >7 Dawson (lanthanide derivative, belt)
K7[a1-LaP2W17O61] 4647 >70 Dawson (lanthanide derivative, belt)
{N(C4H9)4}4 a-[PW11O39{Sn(CH2)2CONBn2}] 4018 >70 Keggin (organic derivative)
{N(C4H9)4}4 a-[PW11O39{Sn(CH2)2CONC5H10}] 3906 >70 Keggin (organic derivative)
{N(C4H9)4}4 a-[PW11O39{Sn(CH2)2CONHCy}] 3920 >70 Keggin (organic derivative)
{N(C4H9)4}4 a-[PW11O39{Sn(CH2)2CONHBn}] 3928 >70 Keggin (organic derivative)
{N(C4H9)4}4 a-[PW11O39{Sn(CH2)2CONH-p-C6H4OMe}] 3944 >70 Keggin (organic derivative)
{N(C4H9)4}4 a-[PW11O39{Sn(CH2)2CONHCH2-m-C6H4CH2NHBoc}] 4057 >70 Keggin (organic derivative)
K7[PW11O39] 3320 1000 Lacunary Keggin
{N(C4H9)4}3 [PMo12O40] 2548 >50 Keggin
H3[PMo12O40] 1829 >50 (1000) Keggin
For IC50 determination, SEMs never exceeded 10%. All of the Preyssler structures exhibited a remarkable in vitro inhibitory power toward CK2, with
IC50 values% 5 nM (calculated at 100 mM ATP). This property is not related to the presence of lanthanides, but to the POM framework, as the lantha-
nide-Dawson structures are less active. In turn, comparison of Dawson and Keggin ions with the same organic side chain indicates that the moderate
activity of the Dawson derivatives is mostly related to their underlying inorganic structure. Keggin ions with equivalent organic groups are much less
active. HPA-23 has a fairly low IC50 value, only slightly higher than the Preyssler compounds and in line with the most active Dawson structures.POM structures are known to depend on concentration, pH,
and buffer characteristics (Pope, 2003). Utmost care therefore
has to be taken when establishing a structure-activity relation-
ship for POMs because the precise structures present at the
low concentrations of biological experiments are difficult to de-
termine (Hill et al., 1990). The Preyssler anions are known to be
very stable in neutral to slightly basic aqueous solutions, and
the organotin-substituted phosphotungstates are kinetically sta-
ble at neutral pH for the time of the present measurements.
These POMs are likely to be intact during the kinase assays.
As the lanthanide phosphotungstates with Dawson structure
have similar activity as the organotin Dawson phosphotung-
states, they are probably also intact during the assay. At least,
they are not hydrolyzed into small fragments, as smaller POMs
are inactive. In this context, it is surprising to find the DawsonChemistry & Biology 15POM [P2Mo18O62]
6 as the most active compound, because
this POM is known to be hydrolyzed very rapidly at neutral pH.
We confirmed rapid hydrolysis in the buffer solution by UV-vis
spectroscopy (t1/2 < 5 min at 30 mM). However, the components
MoO4
2 and PO4
3, when tested individually or in combination,
are inactive. This intriguing activity of [P2Mo18O62]
6 prompted
us to investigate this compound further.
[P2Mo18O62]
6 as a Selective Kinase Inhibitor
We examined the inhibitory effects of [P2Mo18O62]
6 on a panel
of 29 recombinant serine/threonine and tyrosine kinases in-
volved in cell signaling (Table S2). At 100 nM, [P2Mo18O62]
6
inhibited CK2 by more than 95%, but it had almost no effect on
the other protein kinases tested, apart from GSK3b and c-Src.
However, the IC50 values for these kinases (GSK3b, 27 nM;, 683–692, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 685
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higher than the IC50 value determined for CK2 (1.4 nM). Thus,
for these different kinases, [P2Mo18O62]
6 shows greater than
40-fold selectivity for CK2 over 28 other kinases tested. By com-
parison to other published CK2 inhibitors used as benchmarks
(Table S3), we can conclude that [P2Mo18O62]
6 is one of the
most selective CK2 inhibitors.
Mechanism of CK2 Inhibition by [P2Mo18O62]
6
The low IC50 exhibited by the Preyssler and Dawson structures
for CK2 were even lower than the CK2 molarity in the assay
(50 nM). This observation led us to explore more thoroughly the
mechanism of action of CK2 inhibition by POMs. POMs often
induce protein aggregation through multivalent electrostatic
interactions (Lee et al., 2005; Tajima, 2004). Thus, recombinant
CK2a was incubated with increasing concentrations of
[P2Mo18O62]
6 in the assay medium. After ultracentrifugation, a
western blot analysis of the supernatants did not show any evi-
dence for POM-induced precipitation of CK2a for concentra-
tions below 10 mM (Figure S1). Other possible mechanisms of
inhibition consist of either complexation of several CK2 mole-
cules by one [P2Mo18O62]
6 or fragmentation of the POM into
several inhibitory moieties. To explore the former hypothesis, we
carried out sucrose density gradient sedimentation analysis
(Valero et al., 1995).
Recombinant CK2a was analyzed under catalytic conditions
by velocity sedimentation through sucrose gradients containing
different [P2Mo18O62]
6 concentrations. In the absence of POM,
the enzyme sedimented as a single peak with an approximate
3.5 S sedimentation coefficient corresponding to its monomeric
form (Figure S2). This sedimentation behavior was not affected
by the presence of [P2Mo18O62]
6 at concentrations up to 100 nM.
Aggregated forms of CK2a sedimenting at the bottom of the tube
were only detected in the presence of 1 mM [P2Mo18O62]
6. Thus,
we can conclude that in the presence of nanomolar concentra-
tions of POM, CK2a does not form oligomeric structures.
We propose that the powerful inhibition of CK2 by POM could
be due, at least for [P2Mo18O62]
6, to fragments of this com-
pound. This would be consistent with the fact that phosphomo-
lybdates undergo multiple equilibria depending on medium
composition (Pettersson et al., 1986). Therefore, we tested the
inhibitory activity of [P2Mo18O62]
6 after prior incubation in the
kinase assay buffer (Figure S3). One should keep in mind that
UV-vis spectroscopy showed fast hydrolysis of [P2Mo18O62]
6
under these conditions. It was observed that the inhibitory activ-
ity of [P2Mo18O62]
6 vanished after prior incubation in buffer, but
remained unchanged after 30 min of incubation at 25C in a BSA-
containing assay medium. These results give clear evidence that
the active form of the POM is a particular protein-stabilized prod-
uct, since hydrolysis in protein-free buffer leads to inactive com-
pounds. This is reminiscent of the POM fragments identified in
the Mo/W storage protein from Azotobacter vinelandii. (Schem-
berg et al., 2007) Some of those fragments also occur only in
the protein environment and cannot be isolated as free entities.
It is thus not possible to use speciation data of phosphomolyb-
dates in water (Pettersson et al., 1986; Himeno et al., 1999;
Briand et al., 2002) to determine the active structure. The pro-
tein-stabilized form of the POM issued from [P2Mo18O62]
6 might
or might not be different in BSA and CK2, but both proteins block686 Chemistry & Biology 15, 683–692, July 21, 2008 ª2008 Elsevierthe total hydrolysis of [P2Mo18O62]
6, and the BSA-stabilized
form also inhibits CK2.
Spectroscopic studies to establish the structures of the active
CK2-bound form of POMs have been unsuccessful so far. It
has also not been possible to analyze the complex POM-CK2
by ESI-MS, since the protein was not in its native form in buffer
solutions compatible with that technique. However, the fact that
the rapid hydrolysis of [P2Mo18O62]
6 appears to be correlated
with the loss of activity highlights the importance of a particular
POM composition and structure that can undergo specific inter-
actions with CK2. As we cannot give the formula of the active
form, we continue to use the formula of the administered form,
[P2Mo18O62]
6, in the subsequent sections.
To define the biochemical mechanism of action of
[P2Mo18O62]
6, we next examined the effects of increasing con-
centrations of ATP or peptide substrate on the inhibitory activity
of the compound by using steady-state analysis. The values from
individual samples were analyzed and plotted as a function of
inhibitor concentration. Lineweaver-Burk inhibition plots showed
that, in the presence of a saturating peptide substrate concen-
tration (600 mM), [P2Mo18O62]
6 can bind to either the CK2-pep-
tide substrate complex (Ki = 7 nM) or the CK2-ATP-peptide
substrate complex (Ki = 5.3 nM), suggesting a mixed inhibition
of CK2 by [P2Mo18O62]
6 with respect to ATP (Figure 2A).This in-
dicates that [P2Mo18O62]
6 is not an ATP site-directed inhibitor.
The effects of increasing concentrations of peptide substrate
on the inhibitory activity of the compound in the presence of
saturating ATP concentration (100 mM) was examined (Fig-
ure 2B). Steady-state kinetic analysis reveals that the apparent
Km for peptide substrate is invariant, a characteristic of noncom-
petitive inhibition, [P2Mo18O62]
6 being able to bind equally well
to the CK2-ATP or the CK2-ATP-peptide substrate complex (Ki =
6.5 nM). This behavior provides evidence that [P2Mo18O62]
6 is
not a peptide substrate site-directed inhibitor.
Binding Site of [P2Mo18O62]
6
We next searched for a putative POM-binding site on CK2a
by using four complementary approaches: (1) kinase assay
with CK2 holoenzyme, (2) affinity chromatography with an
immobilized POM, (3) trypsin proteolysis, and (4) site-directed
mutagenesis.
First, a CK2 kinase assay was performed with either CK2a
alone or reconstituted CK2 holoenzyme (CK2a2/CK2b2) (Valero
et al., 1995) to determine the influence of the regulatory CK2b
subunit on the inhibitory activity of [P2Mo18O62]
6. Similar IC50
values were obtained, indicating that the binding of CK2b on
CK2a does not affect the kinase sensitivity for the inhibitor,
thus ruling out the involvement of the CK2a/CK2b interface in
the interaction (Figure 3).
To understand the precise nature of the interactions of POMs
with CK2a, we next performed binding assays in which re-
combinant CK2a was incubated with a biotinylated Keggin
POM (BK). A CK2 kinase assay performed in the presence of
BK showed that this functionalized POM inhibits CK2a through
a similar mechanism as the Dawson ion [P2Mo18O62]
6 (mixed
inhibition with respect to ATP) (Figure S4). Recombinant CK2a
was incubated with BK or biotinylated CK2b immobilized on
streptavidine-Sepharose beads. The results presented in
Figure 4A indicate the presence of CK2a associated to theLtd All rights reserved
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the corresponding supernatants. Thus, like with CK2b, a high-
affinity interaction was detected between the Keggin compound
and CK2a. This fact allowed us to perform affinity chromatogra-
phy on immobilized BK in the presence of CK2b, ATP, CK2 pep-
tide substrate, and TBB (Figure 4B). CK2a was not displaced
from the BK resin by a stoichiometric amount of CK2b (in accor-
dance with the similar IC50 values of POM for the CK2 holoen-
zyme and for the isolated CK2a). In addition, neither ATP nor
TBB nor a CK2 peptide substrate interfered with the ability of
CK2a to bind to the immobilized POM.
Figure 2. Steady-State Kinetic Analysis of [P2Mo18O62]
6/CK2 Com-
plexation
(A and B) CK2 activity was determined as described in the Experimental
Procedures either in the absence or in the presence of the indicated
[P2Mo18O62]
6 concentrations. (A) Steady-state kinetic analysis carried out
with a saturating peptide substrate concentration (600 mM). (B) Steady-state
kinetic analysis carried out with a saturating ATP concentration (100 mM).
The data represent means of experiments run in triplicate, with SEM never
exceeding 10%.Chemistry & Biology 15Collectively, these data indicate that the POM likely binds out-
side the CK2a/CK2b interface and the ATP/peptide-binding
pocket.
Next, samples of CK2a complexed with [P2Mo18O62]
6 were
subjected to partial proteolysis in the presence of trypsin, and
the resultant proteolytic fragments were separated by SDS-
PAGE. The results depicted in Figure 5A show that whereas
CK2a was almost completely degraded after 30 min, the
CK2a-[P2Mo18O62]
6 complex led to the generation of two
low-molecular weight fragments (6.3 and 5.6 kDa) that were re-
sistant to trypsin degradation for up to 60 min. Under similar
conditions, trypsin-induced degradation of BSA was not af-
fected by the presence of [P2Mo18O62]
6 (not shown). Thus,
the two protein fragments that are protected from degradation
owing to a high-affinity interaction of [P2Mo18O62]
6 with CK2a
may represent minimal interacting domains. Therefore, these
fragments were extracted from the SDS-PAGE gel and sub-
jected to amino acid sequencing analysis. This analysis revealed
that the 6.3 kDa fragment (residues 22–68) contains the N-termi-
nal domain and three b strands (b1, b2, and b3). Strands b1 and
b2 are the major contacts with the CK2b dimer at the interface.
This region also displays the glycine-rich loop (Figure 5B).
(Niefind et al., 2001) The 5.6 kDa fragment (residues 192–244)
consists of the activation segment and two a helices (aF and
aG). Thus, these protected fragments may contain putative
inhibitor binding site(s).
Finally, to investigate whether introducing mutations into helix
C and the activation segment affects the [P2Mo18O62]
6 inhibi-
tory potency, we mutated several residues located in or
close to the identified trypsin resistant fragments (Figure 5C).
[P2Mo18O62]
6 was tested for its ability to inhibit the activity of
wild-type (WT) and K49A/F54L, K74A, and R191A CK2amutants
Figure 3. Dose-Dependent Inhibition of Two Forms of CK2 by
[P2Mo18O62]
6
Activity assays of the isolated CK2 catalytic subunit (diamonds) or the CK2 ho-
loenzyme (squares) were performed as described in Experimental Procedures
in the presence of increasing [P2Mo18O62]
6 concentrations. The data repre-
sent means of two independent experiments., 683–692, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 687
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ments with Biotinylated POM
(A–B) (A) Recombinant CK2a binds to Biotin-
Keggin polyoxometalate. CK2a (240 ng) was incu-
bated with (A) streptavidine-Sepharose beads
alone or with streptavidine-Sepharose beads
loaded with (B) biotinylated Keggin or biotinylated
CK2b. After centrifugation of the beads, CK2 activ-
ity was assayed in the supernatants, and the pres-
ence of CK2a associated to the beads was de-
tected by western blot. (B) Binding specificity of
Biotin-Keggin polyoxometalate on CK2a. Sephar-
ose-immobilized Biotin-Keggin polyoxometalate
was incubated with CK2a (240 ng) in the absence or presence of a stoichiometric amount of CK2b, 100 mM ATP, 100 mM CK2 peptide substrate, or 100 mM
TBB. After extensive washing, the bound protein was resolved by SDS-PAGE and was immunodetected with anti-CK2a.(Figure 5D). It was observed that the sensitivity of these CK2a
mutants to [P2Mo18O62]
6 inhibition was significantly affected,
resulting in a shift to a higher IC50. Conversely, other mutations
in the identified protected fragments (K198A) or outside these
fragments (R80A) were without effect (not shown). Thus, specific
mutations in key structural elements like the glycine-rich loop,
helix C, and activation segment weaken the CK2a sensitivity to
[P2Mo18O62]
6 inhibition.
Cell Assay
Pharmacokinetic characteristics of POMs are critical issues for
developing these compounds as chemotherapeutic agents.
Therefore, we investigated whether [P2Mo18O62]
6 could inhibit
CK2 in living cells by using a cellular CK2 activity assay. HeLa
cells expressing a CK2 peptide substrate reporter were
incubated with TBB, [P2Mo18O62]
6, or DMSO as a control
(Figure 6A). The cellular phosphorylation of the CK2 substrate
reporter was strongly inhibited in TBB-treated cells. In contrast,
this phosphorylation was not affected in cells incubated with
[P2Mo18O62]
6. This could result from the high charge of thePOM framework that might prevent their delivery inside the cells
or by degradation of the active compound in the cellular environ-
ment. To determine whether [P2Mo18O62]
6 inhibits CK2 in
a complex cellular protein mixture, we used whole brain tissue
lysates as a source of CK2 that potentially conserves, at least
in part, the physiological environment of the kinases. This cell-
free system may be seen as a compromise between living cells
and recombinant CK2, as it preserves, to some extent, the bio-
chemical context of the target, but is not dependent on the cell
permeability of the POM. Brain extracts were incubated with in-
creasing concentrations of [P2Mo18O62]
6, and CK2 activity was
assayed. It was observed that [P2Mo18O62]
6 inhibited the CK2
activity in a dose-dependent manner with an IC50 value of 0.6 mM
(Figure 6B). Next, we examined the effect of [P2Mo18O62]
6 on
the phosphorylation of endogenous CK2 substrates present
in brain extracts. As CK2 is one of the few kinases using GTP
as a phosphate donor, tissue extracts were incubated with
[g-32P]GTP-MgCl2 (Figure 6C). Under these experimental condi-
tions, several phosphorylated proteins were detected. The phos-
phorylation of three of them was enhanced by the addition ofFigure 5. Localization of the [P2Mo18O62]
6
Binding Site
(A) Time course tryptic proteolysis of the
[P2Mo18O62]
6-CK2a complex. [P2Mo18O62]
6-
CK2a complexes were purified by gel-exclusion
chromatography and subjected to tryptic proteol-
ysis for the indicated time. The resultant proteo-
lytic fragments were separated by SDS-PAGE.
After completion of the tryptic proteolysis, the
low-molecular weight 6.3 and 5.6 kDa fragments
were extracted from the gel and sequenced by
Edmann degradation.
(B) The crystal structure of CK2a (adapted from
Niefind et al., 2001) and trypsin-resistant frag-
ments (6.3 kDa, residues 22–68; 5.6 kDa, residues
192–244) are highlighted in dark gray.
(C) Model showing mutations within CK2a affect-
ing [P2Mo18O62]
6 activity. Mutations K49A/F54L,
K74A, and R191A are depicted in black balls and
sticks in the CK2a ribbon.
(D) Inhibitory effect of [P2Mo18O62]
6 on WT (dia-
monds) and K49A/F54L (triangles), K74A (circles),
and R191A (squares) CK2a mutants.
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6
in a Cellular Environment
(A) Lack of CK2 inhibition by [P2Mo18O62]
6 in liv-
ing cells. HeLa cells expressing a fusion construct
consisting of several repeats of a CK2 peptide
substrate fused to GFP were incubated for 48 hr
with 100 mM TBB, [P2Mo18O62]
6, or an equivalent
amount of DMSO as a control. Proteins from the
cell extracts were resolved by native 12% PAGE
and immunoblotted with anti-GFP. The CK2-de-
pendent phosphorylated form of the CK2 peptide
substrate reporter is indicated by the arrow.
(B) Inhibition of CK2 by [P2Mo18O62]
6 in a complex
protein mixture. Murine brain extracts were incu-
bated with increasing [P2Mo18O62]
6 concentra-
tions (0.001–10 mM), and CK2 activity was assayed
as described in Experimental Procedures. Each
point is the mean of duplicate assays (variation is
indicated by error bars) and designates CK2 activ-
ity expressed as a percentage of activity in the
absence of compound.
(C) Inhibition of CK2 substrate phosphorylation
in murine brain extracts by [P2Mo18O62]
6. Ex-
tracts were incubated with [g-32P]GTP-MgCl2 in
the absence or presence of recombinant CK2
subunits, 10 or 100 mM TBB, and 1–100 mM
[P2Mo18O62]
6. Proteins were analyzed by SDS-PAGE, and phosphoproteins were visualized by autoradiography. The arrows show endogenous CK2 substrates.
The asterisk indicates a protein substrate for a CK2-unrelated kinase.recombinant CK2 and was strongly inhibited by TBB, indicating
that they are potential CK2 substrates. The phosphorylation of
these CK2 substrates was inhibited by [P2Mo18O62]
6 in a
dose-dependent manner. This is combined evidence that
[P2Mo18O62]
6 is a CK2 inhibitor in this cell-like environment.
SIGNIFICANCE
Mechanisms of action and cellular targets of POMs are
poorly defined, with only few documented cases. (Herve´
et al., 1983; Hill et al., 1990; Crans, 1993; Sarafianos et al.,
1996; Judd et al., 2001; Mitsui et al., 2006; Mu¨ller et al.,
2006; Hu et al., 2007). Our work reports that POMs are pow-
erful nonclassical CK2 inhibitors, with [P2Mo18O62]
6 being
one of the most potent and selective CK2 inhibitors. Recur-
rent features of biologically active POMs are their high
charge and the large size of their framework. However, in
our study, the active form is a protein-stabilized degradation
product. Identification of this active product by crystalliza-
tion of POM-CK2 complexes is underway.
The pharmacokinetic characteristics (distribution, clear-
ance) of the POMs presented here make them very unlikely
new drugs. Yet the design of functionalized POMs coupled
to organic molecules that would tune the parameters might
lead to viable candidates. In addition, the study of their orig-
inal inhibition mode contributes to a better understanding of
the functioning of CK2, whichwill allow for the design of new
drugs with different chemical compositions, but similar inhi-
bition profiles.
CK2 inhibition by [P2Mo18O62]
6 is a mixed inhibition with
respect to ATP and a noncompetitive one toward the
phosphoacceptor peptide substrate. Moreover, no differ-
ences in POM sensitivity between the isolated CK2a sub-Chemistry & Biology 15unit and the holoenzyme were observed, and the POM-
CK2 interaction was also not affected by ATP, TBB, or
a CK2 peptide substrate. This indicates that the POM-
binding site does not involve either the ATP/peptide-bind-
ing pocket or the CK2b-binding domain. (Niefind et al.,
2001). Proteolytic degradation of the CK2a-inhibitor com-
plex and site-directed mutagenesis revealed that inhibitor-
interacting domains contain key structural elements like
the activation segment. This segment is stabilized by con-
tacts to the N-terminal region that maintain CK2 in an active
state (Niefind et al., 2001; Sarno et al., 2002). Thus, docking of
[P2Mo18O62]
6 to the activation segment may disrupt these
contacts, locking CK2 in an inactive conformation. Biophys-
ical experiments aiming at deciphering this unexpected
inhibition mode are underway.
EXPERIMENTAL PROCEDURES
Polyoxometalates
The following POMs were prepared according to published procedures and
were characterized by NMR and/or IR spectroscopy: K6[P2Mo18O62] (Briand
et al., 2002) (by using KCl instead of NH4Cl); {N(C4H9)4}7[P2W17O61SnR] (R =
organic side chain) (Bareyt et al., 2003, 2005); {N(C4H9)4}4[PW11O39SnR] (Sa-
zani and Pope, 2004; Bareyt et al., 2005); K7[LnP2W17O61] (Ln = lanthanide)
(Bartis et al., 1997); K7[PW11O39] (Contant, 1987); Na17[(P2W15O56)2Co4-
(H2O)(OH)] (Ruhlmann et al., 2002); K6[P2W18O62], K12H2a-[P2W12O48],
K28Li5H7[P8W48O184], and Na12[P2W15O56] (Contant, 1990); {N(C4H9)4}5-
H4[P2Nb3W15O62] and K8H[P2V3W15O62] (Hornstein and Finke, 2002); and
{N(C4H9)4}2[Mo6O19] (Klemperer, 1990). All other POMs were part of the
National Cancer Institute (NCI) library or were commercially available and
were used as received.
BK
TBA4[PW11O39{SnCH2CH2CO-m-NHCH2C6H4CH2NH-d-biotine}] was pre-
pared by adapting our published procedure for coupling organic molecules, 683–692, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 689
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plete procedure and full characterization are given in the Supplemental Data.
In Vitro Kinase Assays
Human recombinant CK2a was expressed in Escherichia coli and purified to
homogeneity as previously described (Heriche et al., 1997). CK2 assays
were performed in a final assay volume of 18 ml containing 3 ml compound,
3 ml CK2a (20 ng), and a mixture containing 1 mM of the peptide substrate
RRREDEESDDEE, 10 mM MgCl2, and [g-
32P]ATP. The final concentration of
ATP was 100 mM. Assays were performed at room temperature for 5 min
before termination by the addition of 60 ml 4% TCA. 32P incorporation in the
peptide substrate was determined as described previously (Filhol et al., 1991).
Screening of a Chemical Library
A library of low-molecular weight compounds was obtained from the NCI, Be-
thesda, Maryland. For more information, see http://dtp.nci.nih.gov. Auto-
mated screening of compounds from the Structural Diversity Set and the
Mechanistic Diversity Set were performed at 1.5 and 15 mM in 96-well plates
by using a TECAN Genesis robot (http://www-dsv.cea.fr/cmba). CK2 activity
was assayed for 30 min at room temperature in a final volume of 30 ml contain-
ing 10 ml compounds or DMSO controls, 10 ml CK2a (50 ng), and 10 ml of a mix-
ture containing the peptide substrate and ATP at a final concentration of
100 mM and 10 mM, respectively. The final concentration of DMSO in the
enzyme assay was less than 3.33%. At the end of the reaction, the kinase
activity was determined by using the luminescence-based Kinase-Glo assay
(Promega) according to the manufacturer’s recommendations and BMG’s
FLUOstar microplate reader. This assay relies on the use of ATP depletion
as a read-out for kinase activity.
Velocity Sedimentation
Linear 5%–20% (w/v) sucrose gradients were prepared in the following buffer:
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 20 mM MgCl2,100 mM ATP supple-
mented with various concentrations of [P2Mo18O62]
6 (c = 0 to 1000 nM, as
indicated in Figure S2). For each experiment, samples were prepared in
50 ml of the previous buffer prior to loading by adding first CK2 then POM. Gra-
dients were centrifuged at 4C for 8 hr at 200,0003 g and were fractionated by
pipetting 125 ml aliquots. For each condition, identical gradients were run by
using horseradish peroxydase (3.5S) and b-galactosidase (12S) as sedimenta-
tion markers, which were detected by SDS-PAGE followed by silver staining.
Selectivity of the Polyoxometalate Inhibitor
To assess the degree of selectivity of the most effective POM, namely,
[P2Mo18O62]
6, it was tested at 100 nM concentration for its ability to inhibit
a panel of 29 recombinant protein kinases by using the Kinase Profiler Assay
(Upstate). Final ATP concentration in the assay was 100 mM. IC50 values for
selected kinases were determined by using a range of ten concentrations of
[P2Mo18O62]
6.
Proteolysis Mapping
A sample of CK2a (90mg) was diluted in 135ml 50 mM Tris-HCl (pH 7.4), 150 mM
NaCl and was incubated for 20 min at 23C in the presence or absence of
63 mM [P2Mo18O62]
6. CK2a-[P2Mo18O62]
6 complexes were recovered by
gel-filtration by using Biospin 6 chromatography columns (Biorad) according
to the manufacturer’s recommendations and were subjected to time course
proteolysis in the presence of 0.9 mg trypsin. Protein fragments were resolved
by 18% SDS-PAGE and Coomassie blue staining. Low-molecular weight
fragments were extracted from the gel and subjected to protein sequence
determination.
Protein Sequence Determination
Amino acid sequencing analysis was performed by using an Applied Biosys-
tems gas-phase sequencer model 492. Phenylthiohydantoin amino acid deriv-
atives generated at each sequencing cycle were identified and quantified
on-line with an applied Biosystems Model 140C HPLC system. The proce-
dures and reagents used were as recommended by the manufacturer. Reten-
tion times and integration values of peaks were compared to the chromato-
graphic profile obtained for a standard mixture of derivatized amino acids.690 Chemistry & Biology 15, 683–692, July 21, 2008 ª2008 ElsevierPolyoxometalate-CK2a Binding Assay
Biotin-Keggin polyoxometalate (0.1 mM) or Biotin-CK2b (0.1 mM) were incu-
bated for 30 min at 4C with Streptavidin-agarose beads (Sigma). After wash-
ing in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, beads were incubated for 15 min
at 4C with CK2a (240 ng). The agarose beads were then centrifuged for 2 min
at 14,000 rpm, and 3 ml supernatant was assayed for CK2 activity. The beads
were washed in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and the presence of
CK2a associated to the beads was detected by western blot.
Construction of Plasmids Expressing CK2a Mutants and Protein
Expression
CK2amutants were obtained from the pET28-CK2a (full length)/GST-express-
ing plasmid (Filhol et al., 2003) by using the Quick change site-directed muta-
genesis kit (Stratagene). The following primers were used:
50-CGAAAATTAGGCCGAGGCGCATACTCTGAAGTACTTGAAGCC-30
(K49A/F54L-forward),
50-GGCTTCAAGTACTTCAGAGTATGCGCCTCGGCCTAATTTTCG-30
(K49A/F54L-reverse),
50-GTTAAAATTCTGAAGCCTGTTGCAAAGAAGAAAATCAAGCGTG-30
(K74A-forward),
50-CACGCTTGATTTTCTTCTTTGCAACAGGCTTCAGAATTTTAAC-30
(K74A-reverse),
50-GGAGTACAATGTCGCAGTGGCCTCGAGATATTTCAAAGGACC-30
(R191A-forward), and
50-GGTCCTTTGAAATATCTCGAGGCCACTGCGACATTGTACTCC-30
(R191A-reverse).
All mutations were verified by DNA sequencing.
Wild-type and mutant CK2a were produced by using standard protein puri-
fication methods. Briefly, they were expressed in Escherichia coli BL21 (2 hr
with 0.5 mM IPTG), and proteins were purified by using glutathione Sepharose
beads (GE Healtcare). The retained fusion protein was cleaved by using 60 U
thrombin (Sigma), and the CK2a proteins were then eluted in 50 mM Tris-HCl
(pH 7.4) containing 150 mM NaCl, 2% glycerol, 1 mM DTT, and protease inhib-
itors. Proteins were quantified by a Bradford assay, and the quality of the
purification was asserted by SDS-PAGE analysis.
Cellular CK2 Activity Assay
The assay will be described in detail elsewhere. Briefly, a CK2 activity reporter
plasmid (pEYFPc1-SbS), which consists of several repeats of a CK2 peptide
substrate fused to EYFP, was transfected in HeLa cells. Transfected cells
were incubated for the indicated time with fresh medium containing the com-
pounds. Then, 50 mg cellular proteins was resolved on a 12% native-polyacryl-
amide gel. After electrotransfer, the membrane was immunoblotted with the
mAb anti-GFP (Roche), followed by incubation with a goat anti-mouse-HRP
secondary antibody (Sigma), and YFP was revealed with the ECL plus western
blot detection system (GE Healthcare).
SUPPLEMENTAL DATA
Supplemental Data three tables, four figures, and Supplemental Experimental
Procedures and can be found with this article online at http://www.chembiol.
com/cgi/content/full/15/7/683/DC1/.
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